Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma-Reference-Cited by-同舟云学术

Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma

Published:2018-08-20 Issue:2 Volume:246 Page:141-153
ISSN:0022-3417
Container-title:The Journal of Pathology
language:en
Short-container-title:J. Pathol

Author:

Liu Zebing¹²³^ORCID,Cai Ying¹²⁴,Yang Yu⁵,Li Anqi¹²,Bi Rui¹²,Wang Lisha⁶,Shen Xiaohan¹²,Wang Weige¹²,Jia Yijun¹²,Yu Baohua¹²,Cao Bing¹²,Cui Wenli¹²,Wei Ping¹²,Zhou Xiaoyan¹²⁷

Affiliation:

1. Department of Pathology; Fudan University Shanghai Cancer Center; Shanghai PR China

2. Department of Oncology, Shanghai Medical College; Fudan University; Shanghai PR China

3. Department of Pathology, Renji Hospital, School of Medicine; Shanghai Jiao Tong University; Shanghai PR China

4. Department of Pathology; Wuxi People's Hospital Affiliated to Nanjing Medical University; Wuxi Jiangsu PR China

5. Scientific Research Center, Shanghai Public Health Clinical Center; Fudan University; Shanghai PR China

6. Michigan Center for Translational Pathology; University of Michigan Medical School; Ann Arbor MI USA

7. Institute of Pathology; Fudan University; Shanghai PR China

Funder

National Natural Science Foundation of China

Shanghai Key Developing Disciplines Program

Publisher

Wiley

Subject

Pathology and Forensic Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/path.5108/fullpdf

Reference45 articles.

1. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning;Shipp;Nat Med,2002

2. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies;Bhalla;J Clin Oncol,2005

3. Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells;Buurman;Gastroenterology,2012

4. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer;Minucci;Nat Rev Cancer,2006

5. Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors;Gloghini;Br J Haematol,2009

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the ubiquitin pathway in lymphoid malignancies;Cancer Letters;2024-07

2. The biology and treatment of Epstein-Barr virus-positive diffuse large B cell lymphoma, NOS;Heliyon;2024-01

3. ASAP2 interrupts c-MET-CIN85 interaction to sustain HGF/c-MET-induced malignant potentials in hepatocellular carcinoma;Experimental Hematology & Oncology;2023-04-15

4. Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL;Cancer Management and Research;2023-02

5. Clinicopathologic features and abnormal signaling pathways in plasmablastic lymphoma: a multicenter study in China;BMC Medicine;2022-12-15